Summary
Gilead Sciences, Inc. (GILD) filed an 8-K on July 18, 2005, reporting a significant material definitive agreement. The company, along with Royalty Pharma, entered into a Royalty Sale Agreement to purchase all royalties payable by Gilead under an existing license agreement with Emory University. This transaction involves a total purchase price of $525 million, with Gilead contributing $341.25 million (65%) and Royalty Pharma contributing $183.75 million (35%). This agreement effectively restructures the royalty payments for the licensed intellectual property. Gilead will now pay 35% of the previously Emory-owed royalties directly to Royalty Pharma. The transaction is contingent upon certain closing conditions, including the amendment and restatement of the license agreement to incorporate Royalty Pharma and an additional $15 million payment from Gilead to Emory in connection with the agreement amendment. This move suggests Gilead is seeking to manage its future royalty obligations and potentially free up capital.
Key Highlights
- 1Gilead Sciences entered into a Royalty Sale Agreement on July 18, 2005.
- 2The agreement involves the purchase of all royalties payable by Gilead under a license with Emory University.
- 3The total purchase price for these royalties is $525 million.
- 4Gilead will pay $341.25 million (65% of the total price) towards the purchase.
- 5Royalty Pharma will pay $183.75 million (35% of the total price) towards the purchase.
- 6Following the transaction, Gilead will pay 35% of the former Emory royalty amount directly to Royalty Pharma.
- 7The transaction is subject to customary closing conditions, including amendment of the license agreement and an additional $15 million payment to Emory.